SOURCE: IO News Wire

IO News Wire

May 18, 2010 07:30 ET

(OTC: KKUR) to Begin Testing Its 100% Accurate Cancer Detection System

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire.

NEW YORK, NY--(Marketwire - May 18, 2010) -  ChromoCure, Inc. (PINKSHEETS: KKUR) announced that it will begin clinical trials on its 100% accurate and effective cancer detection system on standard "Pap Smears" to test for cervical cancer (http://finance.yahoo.com/news/ChromoCure-Genome-Research-iw-679357101.html?x=0&.v=1).

ChromoCure's claim that it can detect cancer 100% of the time effectively via the "aneuploidy method," has been backed by the Mayo Clinic in a December 2009 article (http://www.mayoclinic.org/news2009-rst/5533.html).

Clinical Trial Phase 1, expected to be finished by April 15th 2011, should enhance the company's ability to apply and be approved for usage in Europe.

For more information, please visit www.chromocure.com.

Other active stocks are Beckman Coulter Inc. (NYSE: BEC), Cepheid (NASDAQ: CPHD) and Abbott Laboratories (NYSE: ABT).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information